Zimbabwe has turned down a major American healthcare agreement valued at 367 million US dollars (272 million pounds) over five years because of Washington's insistence on confidential biological samples.
The decision came to light after a government memo from December was leaked, revealing that Head of State Emmerson Mnangagwa felt the agreement was "skewed".
An official representative has since clarified that the US was demanding access to biological samples for research and commercial purposes while was unwilling to guarantee the resulting advantages from future medical innovations.
"We must now begin the difficult and regrettable process of ending our health assistance in Zimbabwe," stated American envoy to Zimbabwe Pamela Tremont in a statement.
Her embassy noted the US had furnished over $1.9bn as health assistance to Zimbabwe over the last two decades.
A physicians' group in Zimbabwe has urged more dialogue to find a deal acceptable to all parties so the country's critical HIV programme can proceed.
Broader Context
This development follows a similar case in Kenya, where a court blocked a similar deal with the US following legal challenges were filed about the safety of citizens' medical information.
After returning to office last year, US President Donald Trump has slashed overseas assistance and closed the key foreign aid agency.
USAID had managed aid for the American government, but Trump argued its expenditure was "wasteful" and his administration was pursuing government-to-government agreements to enhance openness and responsibility.
According to reports, Sixteen nations in Africa have so far agreed to these new health pacts, constituting more than $18.3bn in committed funds.
Details of the Rejected Agreement
The funds for Zimbabwe was intended to gone towards "HIV/Aids treatment and prevention, TB, malaria, maternal and child health, and preparing for epidemics".
"We are confident this cooperation could have provided extraordinary advantages for Zimbabwean communities, particularly the 1.2 million men, women and children presently on antiretroviral therapy through American-funded programmes," the Ambassador commented.
However, government spokesperson Nick Mangwana argued the arrangement was "asymmetrical".
"Zimbabwe was being asked to provide its genetic material and health information indefinitely, without any corresponding guarantee of benefiting from any scientific breakthroughs – such as vaccines, diagnostics, or treatments – that might result from that shared data," Mangwana explained.
"In essence, our nation would supply the basic resources for scientific discovery with no certainty that the final treatments would be available to our citizens if a new disease outbreak emerge."
National Interest and International Frameworks
Mangwana further said that the American exit from the global health body and its pursuit of one-on-one deals were disrupting structures already set up via the global organization.
Mangwana gave as an example its Pandemic Benefit-Sharing framework designed to manage potential pandemics.
"This system is intended to ensure that when a nation contributes its samples, the benefits – including vaccines and treatments – are distributed fairly, not commercialised exclusively by those with the resources to develop them."
These objections regarding the US deal "are not meant as hostility towards the US," Mangwana stressed.
"We encourage further dialogue with our US partners on how subsequent co-operation could be designed in a way that respects the sovereignty and interests of both nations."
Health Experts Response
Medical experts stated it acknowledged the government's concerns, but suggested that negotiations should continue given that a large portion of the nation's HIV programmes were funded by foreign aid.
"If technical issues exist, including those involving data governance or agreement terms, these can often be resolved via detailed discussion and mutually agreed protections," it commented.
This impasse emphasises the complex tensions between receiving vital international aid and safeguarding national sovereignty in an increasingly data-driven world.